Long-term efficacy of modified-release recombinant human thyrotropin augmented radioiodine therapy for benign multinodular goiter: results from a multicenter, international, randomized, placebo-controlled, dose-selection study
- Fast, Søren
- Hegedüs, Laszlo
- Pinchera, Aldo
- Leung, Angela M
- Vaisman, Mario
- Reiners, Christoph
- Wemeau, Jean Louis
- Huysmans, Dyde A
- Harper, William
- Rachinsky, Irina
- de Souza, Hevelyn Noemberg
- Castagna, Maria G
- Antonangeli, Lucia
- Braverman, Lewis E
- Corbo, Rossana
- Düren, Christian
- Proust Lemoine, Emmanuelle
- Marriott, Christopher
- Driedger, Albert
- Grupe, Peter
- Watt, Torquil
- Magner, James
- Purvis, Annie
- Graf, Hans
- PACINI, FURIO
Publication date
January 2014
DOI Publisher
Mary Ann Liebert Inc ISSN
1050-7256 Citation count (estimate)
15Abstract
Enhanced reduction of multinodular goiter (MNG) can be achieved by stimulation with recombinant human thyrotropin (rhTSH) before radioiodine ((131)I) therapy. The objective was to compare the long-term efficacy and safety of two low doses of modified release rhTSH (MRrhTSH) in combination with (131)I therapy
Add to ORKG